|Synonyms||1-[2-(Diethylamino)ethyl]-3-(p-methoxybenzyl)-2-quinoxalone; Spadon; Spasmium|
|Purity Chemicals||≥99% (HPLC)|
|Appearance||White or slightly yellow, fine powder.|
|Solubility||Soluble in DMSO (10 mg/ml). Insolube in water.|
|Identity||Determined by NMR.|
|Declaration||Manufactured by Chemodex.|
|Other Product Data||
Click here for Original Manufacturer Product Datasheet
|Shipping and Handling|
|Short Term Storage||+20°C|
|Long Term Storage||+4°C|
Keep cool and dry.
Protect from light and moisture.
|Use/Stability||Stable for at least 2 years after receipt when stored at +4°C.|
|Product Specification Sheet|
Quinoxaline compound, originally developed as a spasmolytic drug. Acts as an N-type calcium channel blocker, competitive AMPA receptor antagonist, and non-competitive NMDA receptor antagonist. Antioxidant agent through partial prevention of the formation and the highly active scavenging of hydroxyl radicals. Used to treat inner ear diseases such as tinnitus. Shown to inhibit tumor-promoting factors and potentially useful as a chemotherapeutic agent.
(1) Y. Ishida, et al., Br. J. Pharmacol. 71, 343 (1980) | (2) B. Saletu, et al.; Arzneimittelforsch. 45, 217 (1995) | (3) D.M. Denk, et al.; Acta Otolaryngol. 117, 825 (1997) | (4) H. Nohl, et al.; Biofactors 19, 79 (2003) | (5) G. Haymerle, et al.; Eur. Arch. Otorhinolaryngol. 272, 3451 (2015)